EBA
LYEL icon

Eagle Bay Advisors’s Lyell Immunopharma LYEL Stock Holding History

Eagle Bay Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-560
Closed -$7.17K – 609
2024
Q4 		$7.17K Buy
+560
New +$11.1K ﹤0.01% 622

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Eagle Bay Advisors's LYEL Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Lyell Immunopharma (LYEL) in Q1 2025, closing a stake of 560 shares — an estimated $7.17K sold.

Eagle Bay Advisors first reported a position in LYEL in Q4 2024 and held it in 1 quarter. The position peaked at $7.17K in Q4 2024. 112 funds tracked by Wall St. Rank hold LYEL as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Lyell Immunopharma position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 560 Lyell Immunopharma shares in Q1 2025, an estimated $7.17K.
  • Eagle Bay Advisors first reported a position in Lyell Immunopharma in Q4 2024 and held it in 1 quarter.
  • Eagle Bay Advisors's Lyell Immunopharma position peaked at $7.17K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.